NTP464

NTP464 is a genetically validated antibody therapeutic developed by Nucleome Therapeutics. It is designed to enhance the function of T-regulatory (Treg) cells, thereby resetting the immune system. The primary indication for this drug is inflammation, with a particular focus on autoimmune diseases such as rheumatoid arthritis. Its mechanism of action is mechanistically distinct from standard-of-care therapies and aims to provide a superior alternative to existing third-line drugs in rheumatoid arthritis and potentially other autoimmune indications. As of May 2025, it remains in preclinical development with plans for clinical trials at the start of 2027[1][5].